Tenova Pharmaceuticals  |  SKU: T71119-10mg

Azide-Hexanoyl-Val-Cit-PAB(m-PEG8)-PNP

Regular price £295.02
Size

SOLU-KNEX® cleavable linker features a Val-Cit dipeptide. m-PEG8 is attached to the commonly used self-immolative para-aminobenzyl (PAB) moiety to increase aqueous solubility. The PNP (para-nitrophenyl) moiety serves as an activating leaving group, enabling efficient and selective conjugation of the payload to the linker.

Derived from established ADC linker architectures, SOLU-KNEX® ADC linkers integrate solubilizing moieties—such as PEG, amine-containing groups, or polysarcosine (PSAR), to enhance aqueous solubility. Solubility and physicochemical properties can be finely tuned through selection and combination of these groups, making the linkers highly adaptable for diverse ADC and related applications. SOLU-KNEX® is a registered trademark of Tenova Pharmaceuticals, Inc. For research use only.

Product Name Azide-Hexanoyl-Val-Cit-PAB(m-PEG8)-PNP
Synonyms
CAS Number
Related CAS
Molecular Formula C49H76N10O18
Molecular Weight 1093.199
Purity (HPLC) >= 95%
Solubility DMSO, DMF
Shipping Conditions Shipped on gel packs
Storage Conditions Store at -20°C and protected from light
Shelf Life 12 months after the date of delivery
Regulatory Statement For Research Use Only


References

(1) Yamazoe, S., Poudel, Y., Sega, E., Mukhopadhyay, A., Ramakrishnan, R., Ukairo, O., Liu, S., Akter, R., Sadanala, K., Que, K., Cheng, Q., Kotapati, S., Deshpande, M., Cox, M., Chourey, S., Gupta, A., Kempson, J., Pabbisetty, K., Kaspady, M., … Chekler, E. P. (2025). Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00357

 

Documents 

Datasheet          MSDS

 

Citations

If you know of a paper that uses this product from Tenova Pharma, please let us know.